[Use of recombinant human luteinizing hormone for ovulation stimulation in in vitro fertilization-embryo transfer]. 2010

Shi-ru Xu, and Yuan Li, and Hong Liu, and Hai-yan Li, and Rong Tang, and Qin Gao, and Yan Sheng, and Zi-Jiang Chen
Reproductive Medical Center, Provincial Hospital Affiliated to Shandong University, Jinan, China.

OBJECTIVE To evaluate application of recombinant human luteinizing hormone (r-hLH) used in ovarian stimulation of assisted reproductive technique and impact on outcome of pregnancy. METHODS From Apr. to Jul. 2009, 123 patients with low LH level (< 1 U/L) at day 3 of menstruation and down-regulation of pituitary function undergoing in vitro fertilization-embryo transfer (IVF-ET) in Reproductive Medical Center, Provincial Hospital Affiliated to Shandong University were enrolled in this study, whom were classified into 66 cases treated by r-hLH in r-hLH group and 57 cases without r-hLH treatment in non-r-hLH group. In the mean time, 145 patients with normal level of serum LH (1 - 2 U/L) not given by r-hLH treatment and undergoing IVF-ET were matched as control group. Total amount of gonadotropin, estradiol levels and LH levels on the administration of human chorionic gonadotropin (hCG), number of oocytes retrieved, number of 2PN zygotes, rate of high quality embryos, the rates of implantation and clinical pregnancy were compared among these three groups. RESULTS The level of serum LH on the day of hCG administration were (1.59 ± 0.77) U/L in r-hLH group, (0.54 ± 0.25) U/L in non-r-hLH group and (2.39 ± 1.01) U/L in control group, which reached statistical difference between every two groups (P < 0.05). The rates of high quality embryo were 59.36% in r-hLH group, 57.79% in non-r-hLH group, which were significantly lower than 65.94% in control group, respectively (P < 0.05). The rates of 2PN were 67.62% in r-hLH group and 68.32% in control group, which were significantly higher than 62.84% in non-r-hLH group, respectively (P < 0.05). The rates of implantation of 29.77% in r-hLH group were significantly higher than 18.26% in non-r-hLH group (P < 0.05). The total amount of gonadotropin, estradiol level on the day of hCG administration, the number of oocytes retrieved, and clinical pregnancy rate were not significantly different among those three groups (P > 0.05). CONCLUSIONS The administration of recombinant human luteinizing hormone in patients who are profoundly suppressed after down-regulation with long protocol can get more quality embryos, the higher rates of 2PN and implantation.

UI MeSH Term Description Entries
D007247 Infertility, Female Diminished or absent ability of a female to achieve conception. Sterility, Female,Sterility, Postpartum,Sub-Fertility, Female,Subfertility, Female,Female Infertility,Female Sterility,Female Sub-Fertility,Female Subfertility,Postpartum Sterility,Sub Fertility, Female
D007279 Injections, Subcutaneous Forceful administration under the skin of liquid medication, nutrient, or other fluid through a hollow needle piercing the skin. Subcutaneous Injections,Injection, Subcutaneous,Subcutaneous Injection
D007986 Luteinizing Hormone A major gonadotropin secreted by the adenohypophysis (PITUITARY GLAND, ANTERIOR). Luteinizing hormone regulates steroid production by the interstitial cells of the TESTIS and the OVARY. The preovulatory LUTEINIZING HORMONE surge in females induces OVULATION, and subsequent LUTEINIZATION of the follicle. LUTEINIZING HORMONE consists of two noncovalently linked subunits, alpha and beta. Within a species, the alpha subunit is common in the three pituitary glycoprotein hormones (TSH, LH and FSH), but the beta subunit is unique and confers its biological specificity. ICSH (Interstitial Cell Stimulating Hormone),Interstitial Cell-Stimulating Hormone,LH (Luteinizing Hormone),Lutropin,Luteoziman,Luteozyman,Hormone, Interstitial Cell-Stimulating,Hormone, Luteinizing,Interstitial Cell Stimulating Hormone
D010060 Ovulation The discharge of an OVUM from a rupturing follicle in the OVARY. Ovulations
D010062 Ovulation Induction Techniques for the artifical induction of ovulation, the rupture of the follicle and release of the ovum. Ovarian Stimulation,Ovarian Stimulations,Stimulation, Ovarian,Stimulations, Ovarian
D011247 Pregnancy The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH. Gestation,Pregnancies
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D004624 Embryo Transfer The transfer of mammalian embryos from an in vivo or in vitro environment to a suitable host to improve pregnancy or gestational outcome in human or animal. In human fertility treatment programs, preimplantation embryos ranging from the 4-cell stage to the blastocyst stage are transferred to the uterine cavity between 3-5 days after FERTILIZATION IN VITRO. Blastocyst Transfer,Tubal Embryo Transfer,Tubal Embryo Stage Transfer,Embryo Transfers,Transfer, Embryo,Transfers, Embryo
D004958 Estradiol The 17-beta-isomer of estradiol, an aromatized C18 steroid with hydroxyl group at 3-beta- and 17-beta-position. Estradiol-17-beta is the most potent form of mammalian estrogenic steroids. 17 beta-Estradiol,Estradiol-17 beta,Oestradiol,17 beta-Oestradiol,Aerodiol,Delestrogen,Estrace,Estraderm TTS,Estradiol Anhydrous,Estradiol Hemihydrate,Estradiol Hemihydrate, (17 alpha)-Isomer,Estradiol Monohydrate,Estradiol Valerate,Estradiol Valeriante,Estradiol, (+-)-Isomer,Estradiol, (-)-Isomer,Estradiol, (16 alpha,17 alpha)-Isomer,Estradiol, (16 alpha,17 beta)-Isomer,Estradiol, (17-alpha)-Isomer,Estradiol, (8 alpha,17 beta)-(+-)-Isomer,Estradiol, (8 alpha,17 beta)-Isomer,Estradiol, (9 beta,17 alpha)-Isomer,Estradiol, (9 beta,17 beta)-Isomer,Estradiol, Monosodium Salt,Estradiol, Sodium Salt,Estradiol-17 alpha,Estradiol-17beta,Ovocyclin,Progynon-Depot,Progynova,Vivelle,17 beta Estradiol,17 beta Oestradiol,Estradiol 17 alpha,Estradiol 17 beta,Estradiol 17beta,Progynon Depot
D005260 Female Females

Related Publications

Shi-ru Xu, and Yuan Li, and Hong Liu, and Hai-yan Li, and Rong Tang, and Qin Gao, and Yan Sheng, and Zi-Jiang Chen
February 1994, Zhonghua fu chan ke za zhi,
Shi-ru Xu, and Yuan Li, and Hong Liu, and Hai-yan Li, and Rong Tang, and Qin Gao, and Yan Sheng, and Zi-Jiang Chen
November 1986, Fertility and sterility,
Shi-ru Xu, and Yuan Li, and Hong Liu, and Hai-yan Li, and Rong Tang, and Qin Gao, and Yan Sheng, and Zi-Jiang Chen
September 2012, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology,
Shi-ru Xu, and Yuan Li, and Hong Liu, and Hai-yan Li, and Rong Tang, and Qin Gao, and Yan Sheng, and Zi-Jiang Chen
February 2010, Fertility and sterility,
Shi-ru Xu, and Yuan Li, and Hong Liu, and Hai-yan Li, and Rong Tang, and Qin Gao, and Yan Sheng, and Zi-Jiang Chen
March 2020, Aging,
Shi-ru Xu, and Yuan Li, and Hong Liu, and Hai-yan Li, and Rong Tang, and Qin Gao, and Yan Sheng, and Zi-Jiang Chen
March 1986, Fertility and sterility,
Shi-ru Xu, and Yuan Li, and Hong Liu, and Hai-yan Li, and Rong Tang, and Qin Gao, and Yan Sheng, and Zi-Jiang Chen
July 1996, Fertility and sterility,
Shi-ru Xu, and Yuan Li, and Hong Liu, and Hai-yan Li, and Rong Tang, and Qin Gao, and Yan Sheng, and Zi-Jiang Chen
June 2023, Aging,
Shi-ru Xu, and Yuan Li, and Hong Liu, and Hai-yan Li, and Rong Tang, and Qin Gao, and Yan Sheng, and Zi-Jiang Chen
September 1994, Human reproduction (Oxford, England),
Shi-ru Xu, and Yuan Li, and Hong Liu, and Hai-yan Li, and Rong Tang, and Qin Gao, and Yan Sheng, and Zi-Jiang Chen
October 1985, Nihon Sanka Fujinka Gakkai zasshi,
Copied contents to your clipboard!